Tissue Repair Ltd (ASX:TRP)

Market Cap	6.65M -56.9%
Revenue (ttm)	3.38M +41.7%
Net Income	-3.85M
EPS	-0.06
Shares Out	60.46M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	88,764
Open	0.1200
Previous Close	0.1100
Day's Range	0.1100 - 0.1200
52-Week Range	0.1000 - 0.4800
Beta	0.24
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 4, 2026

About Tissue Repair

Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous leg ulcers; and TR Pro+, a post-procedure gel for the aftercare of acut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: TRP

Financial Performance

In fiscal year 2025, Tissue Repair's revenue was 2.63 million, an increase of 47.04% compared to the previous year's 1.79 million. Losses were -4.24 million, 2.43% more than in 2024.